Hostname: page-component-76d6cb85b7-rxvq6 Total loading time: 0 Render date: 2026-07-21T23:23:48.076Z Has data issue: false hasContentIssue false

Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis

Published online by Cambridge University Press:  19 December 2017

Andrea Cipriani*
Affiliation:
Department of Psychiatry, University of Oxford, UK
Taryn Williams
Affiliation:
Department of Psychiatry and Mental Health and Medical Research Council of South Africa Unit on Anxiety & Stress Disorders, University of Cape Town, South Africa
Adriani Nikolakopoulou
Affiliation:
Department of Clinical Research, Institute of Social and Preventive Medicine, University of Bern, Switzerland
Georgia Salanti
Affiliation:
Department of Clinical Research, Institute of Social and Preventive Medicine, University of Bern, Switzerland
Anna Chaimani
Affiliation:
Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Greece
Jonathan Ipser
Affiliation:
Department of Psychiatry and Mental Health and Medical Research Council of South Africa Unit on Anxiety & Stress Disorders, University of Cape Town, South Africa
Phil J. Cowen
Affiliation:
Department of Psychiatry, University of Oxford, UK
John R. Geddes
Affiliation:
Department of Psychiatry, University of Oxford, UK
Dan J. Stein
Affiliation:
Department of Psychiatry and Mental Health and Medical Research Council of South Africa Unit on Anxiety & Stress Disorders, University of Cape Town, South Africa
*
Author for correspondence: Andrea Cipriani, E-mail: andrea.cipriani@psych.ox.ac.uk

Abstract

Background

Guidelines about post-traumatic stress disorder (PTSD) recommend broad categories of drugs, but uncertainty remains about what pharmacological treatment to select among all available compounds.

Methods

Cochrane Central Register of Controlled Trials register, MEDLINE, PsycINFO, National PTSD Center Pilots database, PubMed, trial registries, and databases of pharmaceutical companies were searched until February 2016 for double-blind randomised trials comparing any pharmacological intervention or placebo as oral therapy in adults with PTSD. Initially, we performed standard pairwise meta-analyses using a random effects model. We then carried out a network meta-analysis. The main outcome measures were mean change on a standardised scale and all-cause dropout rate. Acute treatment was defined as 8-week follow up.

Results

Desipramine, fluoxetine, paroxetine, phenelzine, risperidone, sertraline, and venlafaxine were more effective than placebo; phenelzine was better than many other active treatments and was the only drug, which was significantly better than placebo in terms of dropouts (odds ratio 7.50, 95% CI 1.72–32.80). Mirtazapine yielded a relatively high rank for efficacy, but the respective value for acceptability was not among the best treatments. Divalproex had overall the worst ranking.

Conclusions

The efficacy and acceptability hierarchies generated by our study were robust against many sources of bias. The differences between drugs and placebo were small, with the only exception of phenelzine. Considering the small amount of available data, these results are probably not robust enough to suggest phenelzine as a drug of choice. However, findings from this review reinforce the idea that phenelzine should be prioritised in future trials in PTSD.

Information

Type
Original Articles
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Supplementary material: File

Cipriani et al supplementary material

Appendices 1-16

Download Cipriani et al supplementary material(File)
File 949 KB